Indiana's Medicaid expansion is being closely watched in part because it was spearheaded by then-Gov. Mike Pence, who is now vice president, and his top health consultant, Seema Verma, who now heads the federal Centers for Medicare & Medicaid Services.
With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures.
For more than 50 years, the program for the poor and sick has been required to ferry certain clients to and from medical appointments. But a few states have sought - and received - waivers to that rule.
More doctors now screen their patients for signs of abuse and more agencies place victims' advocates inside health centers. Education and counseling for people experiencing violence is also more widely available in clinics and hospitals.
Hampered by political ideology from the White House that has spurred a focus on overhauling Medicaid benefits, for instance, Medicaid's former CMO says CMS is 'ill-equipped' right now to handle the opioid epidemic.
Former congressional staffers who now work for drug companies often return to the Hill to lobby former co-workers or employees. This raises concerns that pharmaceutical companies could wield undue influence.